Squamous cell carcinoma of head and neck: what internists should know

키워드

참고문헌 (96)

1. Walden MJ, "Head and neck cancer", Semin Roentgenol, 48, pp.75~86 (2013)
2. Siegel RL, "Cancer statistics, 2019", CA Cancer J Clin, 69, pp.7~34 (2019)
3. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015", Cancer Research and Treatment, 50(2), pp.303~316 (2018), 대한암학회
4. Goldenberg D, "Habitual risk factors for head and neck cancer", Otolaryngol Head Neck Surg, 131, pp.986~993 (2004)
5. Maier H, "Tobacco and alcohol and the risk of head and neck cancer", Clin Investig, 70, pp.320~327 (1992)
6. Kutler DI, "High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia", Arch Otolaryngol Head Neck Surg, 129, pp.106~112 (2003)
7. D’Souza G, "Case-control study of human papillomavirus and oropharyngeal cancer", N Engl J Med, 356, pp.1944~1956 (2007)
8. Ang KK, "Human papillomavirus and survival of patients with oropharyngeal cancer", N Engl J Med, 363, pp.24~35 (2010)
9. Fakhry C, "Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma", J Clin Oncol, 32, pp.3365~3373 (2014)
10. Gillison ML, "Prevalence of oral HPV infection in the United States, 2009-2010", JAMA, 307, pp.693~703 (2012)
11. Sonawane K, "Oral human papillomavirus infection : differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014", Ann Intern Med, 167, pp.714~724 (2017)
12. Gillison ML, "Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers", J Natl Cancer Inst, 100, pp.407~420 (2008)
13. Mork J, "Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck", N Engl J Med, 344, pp.1125~1131 (2001)
14. Kim YT, "Burden of human papillomavirus(HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea", Papillomavirus Res, 7, pp.26~42 (2019)
15. Smith EM, "Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers", Int J Cancer, 108, pp.766~772 (2004)
16. Anaya-Saavedra G, "High association of human papillomavirus infection with oral cancer : a case-control study", Arch Med Res, 39, pp.189~197 (2008)
17. Chaturvedi AK, "Effect of prophylactic human papillomavirus(HPV)vaccination on oral HPV infections among young adults in the United States", J Clin Oncol, 36, pp.262~267 (2018)
18. Mittal S, "Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation", Mutat Res Rev Mutat Res, 772, pp.23~35 (2017)
19. Ertosun MG, "E2F1 transcription factor and its impact on growth factor and cytokine signaling", Cytokine Growth Factor Rev, 31, pp.17~25 (2016)
20. Ho GY, "Natural history of cervicovaginal papillomavirus infection in young women", N Engl J Med, 338, pp.423~428 (1998)
21. zur Hausen H, "Papillomaviruses causing cancer : evasion from host-cell control in early events in carcinogenesis", J Natl Cancer Inst, 92, pp.690~698 (2000)
22. McLaughlin-Drubin ME, "Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming", Proc Natl Acad Sci U S A, 108, pp.2130~2135 (2011)
23. Prigge ES, "Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas : a systematic review and meta-analysis", Int J Cancer, 140, pp.1186~1198 (2017)
24. Randen-Brady R, "In situ hybridization for high-risk HPV E6", E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer, 2019, pp.90, 97~105
25. Cancer Genome Atlas Network, "Comprehensive genomic characterization of head and neck squamous cell carcinomas", Nature, 517, pp.576~582 (2015)
26. Oganesyan G, "Critical role of TRAF3in the Toll-like receptor-dependent and-independent antiviral response", Nature, 439, pp.208~211 (2006)
27. Koncar RF, "Comparative molecular profiling of HPV-induced squamous cell carcinomas", Cancer Med, 6, pp.1673~1685 (2017)
28. Lee JY, "Biochemistry. PI3K charges ahead", Science, 317, pp.206~207 (2007)
29. Scheid MP, "PKB", AKT : functional insights from genetic models, 2001, pp.2, 760~768
30. Nichols AC, "High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer", JAMA Otolaryngol Head Neck Surg, 139, pp.617~622 (2013)
31. Jung K, "Targeting phosphoinositide 3-kinase(PI3K)in head and neck squamous cell carcinoma(HNSCC)", Cancers Head Neck, 3, pp.3~ (2018)
32. Chung CH, "p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma", J Clin Oncol, 32, pp.3930~3938 (2014)
33. Butz K, "Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents : repression of E6", E7-oncogene expression and induction of apoptosis, 1996, pp.68, 506~513
34. Liu Y, "Human papillomavirus type 16 E6 and HPV-16 E6", E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents : roles of p53 and caspase activation, 2000, pp.78, 334~349
35. Marur S, "Head and neck squamous cell carcinoma : update on epidemiology, diagnosis, and treatment", Mayo Clin Proc, 91, pp.386~396 (2016)
36. Zhang H, "Survival outcomes of patients with advanced oral cavity squamous cell carcinoma treated with multimodal therapy : a multi-institutional analysis", J Otolaryngol Head Neck Surg, 42, pp.30~ (2013)
37. Nichols AC, "Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma(ORATOR) : an open-label, phase 2, randomised trial", Lancet Oncol, 20, pp.1349~1359 (2019)
38. Richmond RC, "Radiation sensitization of bacterial spores by cis-dichlorodiammineplatinum(II)", Radiat Res, 68, pp.251~257 (1976)
39. Wallner KE, "Effect of cisplatin resistance on cellular radiation response", Int J Radiat Oncol Biol Phys, 13, pp.587~591 (1987)
40. Calais G, "Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma", J Natl Cancer Inst, 91, pp.2081~2086 (1999)
41. Denis F, "Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma", J Clin Oncol, 22, pp.69~76 (2004)
42. Adelstein DJ, "An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer", J Clin Oncol, 21, pp.92~98 (2003)
43. Forastiere AA, "Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer", N Engl J Med, 349, pp.2091~2098 (2003)
44. Wendt TG, "Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer : a randomized multicenter study", J Clin Oncol, 16, pp.1318~1324 (1998)
45. Forastiere AA, "Long-term results of RTOG 91-11 : a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer", J Clin Oncol, 31, pp.845~852 (2013)
46. Bernier J, "Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer", N Engl J Med, 350, pp.1945~1952 (2004)
47. Cooper JS, "Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck", N Engl J Med, 350, pp.1937~1944 (2004)
48. Haddad R, "Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial", Lancet Oncol, 14, pp.257~264 (2013)
49. Cohen EE, "Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer", J Clin Oncol, 32, pp.2735~2743 (2014)
50. Geoffrois L, "Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas : results of the GORTEC 2007-02 phase III randomized trial", J Clin Oncol, 36, pp.3077~3083 (2018)
51. Zhong LP, "Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma", J Clin Oncol, 31, pp.744~751 (2013)
52. Bonner JA, "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck", N Engl J Med, 354, pp.567~578 (2006)
53. Gillison ML, "Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016):a randomised, multicentre, non-inferiority trial", Lancet, 393, pp.40~50 (2019)
54. Mehanna H, "Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer(De-ESCALaTE HPV) : an open-label randomised controlled phase 3 trial", Lancet, 393, pp.51~60 (2019)
55. Tan HK, "Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas : stratification for postsalvage survival", Head Neck, 32, pp.139~147 (2010)
56. Guo T, "Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer", Cancer, 121, pp.1977~1984 (2015)
57. Argiris A, "Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer : an analysis of Eastern Cooperative Oncology Group trials", Ann Oncol, 25, pp.1410~1416 (2014)
58. Joseph AW, "Disease-free survival after salvage therapy for recurrent oropharyngeal squamous cell carcinoma", Head Neck, 38(Suppl 1), pp.E1501~E1509 (2016)
59. Vermorken JB, "Platinum-based chemotherapy plus cetuximab in head and neck cancer", N Engl J Med, 359, pp.1116~1127 (2008)
60. Vermorken JB, "Overview of the efficacy of cetuximab in recurrent and", or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies, 2008, pp.112, 2710~2719
61. Francisco LM, "PD-L1 regulates the development, maintenance, and function of induced regulatory T cells", J Exp Med, 206, pp.3015~3029 (2009)
62. Amarnath S, "The PDL1-PD1axis converts human TH1 cells into regulatory T cells", Sci Transl Med, 3, pp.111~120 (2011)
63. Bauml J, "Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer : results from a single-arm, phase II study", J Clin Oncol, 35, pp.1542~1549 (2017)
64. Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", N Engl J Med, 375, pp.1856~1867 (2016)
65. Harrington KJ, "Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141):health-related quality-of-life results from a randomised, phase 3 trial", Lancet Oncol, 18, pp.1104~1115 (2017)
66. Burtness B, "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study", Lancet, 394, pp.1915~1928 (2019)
67. Pestana RC, "Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent", metastatic head and neck squamous cell carcinoma, 2020, pp.101, 104523~
68. Murphy BA, "Advances in supportive care for late effects of head and neck cancer", J Clin Oncol, 33, pp.3314~3321 (2015)
69. Weber RS, "Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11", Arch Otolaryngol Head Neck Surg, 129, pp.44~49 (2003)
70. van der Woerd B, "Functional outcomes in early(T1", T2)supraglottic cancer : a systematic review, 2018, pp.47, 76~
71. Kumarasiri A, "Changes in pharyngeal constrictor volumes during head and neck radiation therapy : implications for dose delivery", J Cancer Res Ther, 13, pp.218~223 (2017)
72. Jacobi I, "Radiation dose to the tongue and velopharynx predicts acoustic-articulatory changes after chemo-IMRT treatment for advanced head and neck cancer", Eur Arch Otorhinolaryngol, 273, pp.487~494 (2016)
73. Starmer HM, "Swallowing outcomes in patients with oropharyngeal cancer undergoing organ-preservation treatment", Head Neck, 36, pp.1392~1397 (2014)
74. Fung K, "Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer", Int J Radiat Oncol Biol Phys, 63, pp.1395~1399 (2005)
75. Kirsh E, "Patient-reported versus physiologic swallowing outcomes in patients with head and neck cancer after chemoradiation", Laryngoscope, 129, pp.2059~2064 (2019)
76. McClelland S 3rd, "Prophylactic versus reactive gastrostomy tube placement in advanced head and neck cancer treated with definitive chemoradiotherapy : a systematic review", Oral Oncol, 87, pp.77~81 (2018)
77. Lambert L, "Organ preservation with concurrent chemoradiation for advanced laryngeal cancer : are we succeeding", Int J Radiat Oncol Biol Phys, 76, pp.398~402 (2010)
78. Grundmann O, "Sensitivity of salivary glands to radiation : from animal models to therapies. Version 2", J Dent Res, 88, pp.894~903 (2009)
79. Hong CH, "A systematic review of dental disease in patients undergoing cancer therapy", Support Care Cancer, 18, pp.1007~1021 (2010)
80. Deng J, "Dental demineralization and caries in patients with head and neck cancer", Oral Oncol, 51, pp.824~831 (2015)
81. Epstein JB, "Oral complications of cancer and cancer therapy : from cancer treatment to survivorship", CA Cancer J Clin, 62, pp.400~422 (2012)
82. Benson E, "The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas", Oral Oncol, 50, pp.565~574 (2014)
83. Rogers SN, "The development of a patients concerns inventory(PCI)to help reveal patients concerns in the head and neck clinic", Oral Oncol, 45, pp.555~561 (2009)
84. Cohen EE, "American Cancer Society head and neck cancer survivorship care guideline", CA Cancer J Clin, 66, pp.203~239 (2016)
85. Pinto FR, "Tobacco and alcohol use after head and neck cancer treatment: influence of the type of oncological treatment employed", Rev Assoc Med Bras, 57, pp.171~176 (2011)
86. Chen AM, "Tobacco use among long-term survivors of head and neck cancer treated with radiation therapy", Psychooncology, 23, pp.190~194 (2014)
87. Gritz ER, "First year after head and neck cancer : quality of life", J Clin Oncol, 17, pp.352~360 (1999)
88. Funk GF, "Long-term health-related quality of life in survivors of head and neck cancer", Arch Otolaryngol Head Neck Surg, 138, pp.123~133 (2012)
89. Chen AM, "Depression among long-term survivors of head and neck cancer treated with radiation therapy", JAMA Otolaryngol Head Neck Surg, 139, pp.885~889 (2013)
90. Mitchell AJ, "Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls : a systematic review and meta-analysis", Lancet Oncol, 14, pp.721~732 (2013)
91. Shinn EH, "Depression and oropharynx cancer outcome", Psychosom Med, 78, pp.38~48 (2016)
92. Marur S, "E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx. ECOG-ACRIN Cancer Research Group", J Clin Oncol, 35, pp.490~497 (2017)
93. Yom SS, "NRG-HN002 : a randomized phase II trial for patients with p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer", Int J Radiat Oncol Biol Phys, 105, pp.684~685 (2019)
94. Massarelli E, "Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial", JAMA Oncol, 5, pp.67~73 (2019)
95. Ho A, "Abstract PR08: preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations", Mol Cancer Ther, 18(12 Suppl), pp.PR08~ (2019)
96. Anderson CM, "Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer", J Clin Oncol, 37, pp.3256~3265 (2019)

관련 논문AI추천